AZ
Therapeutic Areas
Hualan Biological Engineering Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Seasonal Influenza Vaccine (Split Virion) | Seasonal Influenza Prevention | Approved |
| Human Albumin | Hypoalbuminemia, Shock, Burns | Approved |
| Human Immunoglobulin (IVIG) | Primary Immunodeficiency, Autoimmune Diseases | Approved |
| Human Coagulation Factor VIII | Hemophilia A | Approved |
| Rabies Vaccine (Vero Cell) | Post-exposure Prophylaxis for Rabies | Approved |
| Hepatitis B Vaccine (Recombinant) | Hepatitis B Prevention | Approved |
| ACYW135 Meningococcal Polysaccharide Vaccine | Meningococcal Meningitis Prevention | Approved |
| Pneumococcal Polysaccharide Vaccine (23-valent) | Pneumococcal Disease Prevention | Approved |
Leadership Team at Hualan Biological Engineering
KX
Kang Xuan (安康)
Chairman of the Board
HW
Hou Wenming (侯文铭)
General Manager (CEO)
PR
Pan Ruoyu (潘若瑜)
Deputy General Manager, Chief Financial Officer
XM
Xie Min (谢敏)
Deputy General Manager
ZJ
Zhang Jingtao (张京涛)
Deputy General Manager
WL
Wang Liping (王莉萍)
Board Secretary
WS
Wang Shumin (王淑敏)
Independent Director